Dynamics of Mutant Alleles in Patients with Advanced Essential Thrombocythernia (ET) or Polycythemia (PV) During Pegylated Interferon-Alfa-2A (PEG-IFN-α-2A; Pegasys) Therapy

被引：0
|
作者：
Quintas-Cardama, Alfonso
Abdel-Wahab, Omar [2 ,3 ]
Levine, Ross L. [2 ,3 ]
Manshouri, Taghi [1 ]
Roupie, Anne-Laure [4 ]
Kantarjian, Hagop M. [1 ]
Verstovsek, Srdan [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Leukemia Serv, New York, NY 10021 USA
[4] Univ Paris 05, Paris, France
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：130 / 130
页数：1
相关论文
共 34 条
  • [1] Pegylated Interferon-ALFA-2A (PEG-IFN-α-2A; PEGASYS) Therapy Renders High Clinical and Molecular Response Rates in Patients with Essential Thrombocythemia (ET) and Polycythemia VERA (PV)
    Quintas-Cardania, Alfonso
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Cortes, Jorge
    Richie, Marie Ann
    Borthakur, Gautam
    Verstovsek, Srdan
    [J]. BLOOD, 2008, 112 (11) : 246 - 246
  • [2] Pegylated interferon-alfa-2a (PEG-IFN-α-2A; PEGASYSTM) for essential thrombocythemia (ET) and polycythemia vera (PV):: An update of an ongoing phase II study
    Quintas-Cardama, Alfonso
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    Cortes, Jorge
    Richie, Marie Ann
    Borthakur, Gautam
    Verstovsek, Srdan
    [J]. BLOOD, 2007, 110 (11) : 1036A - 1037A
  • [3] Treatment with pegylated Interferon-Atfa-2A (PEG-IFN-Aα-2A; PEGASYS™) for patients with essential thrombocythemia (ET) and polycythemia vera (PV).
    Quintas-Cardama, Alfonso
    Kantarjian, Hagop
    Giles, Francis
    Cortes, Jorge
    Richie, Mary Ann
    Borthakur, Gautam
    Verstovsek, Srdan
    [J]. BLOOD, 2006, 108 (11) : 307B - 307B
  • [4] High Rates of Molecular Response After Long-Term Follow-up of Patients with Advanced Essential Thrombocythemia (ET) or Polycythemia Vera (PV) Treated With Pegylated Interferon-ALFA-2A (PEG-IFN-α-2A; PEGA-SYS)
    Quintas-Cardama, Alfonso
    Levine, Ross
    Manshouri, Taghi
    Kilpivaara, Outi
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    [J]. BLOOD, 2010, 116 (21) : 206 - 206
  • [5] Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)
    Masarova, Lucia
    Yin, C. Cameron
    Cortes, Jorge E.
    Konopleva, Marina
    Borthakur, Gautam
    Newberry, Kate J.
    Kantarjian, Hagop M.
    Bueso-Ramos, Carlos E.
    Verstovsek, Srdan
    [J]. EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2017, 6
  • [6] Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)
    Lucia Masarova
    C. Cameron Yin
    Jorge E. Cortes
    Marina Konopleva
    Gautam Borthakur
    Kate J. Newberry
    Hagop M. Kantarjian
    Carlos E. Bueso-Ramos
    Srdan Verstovsek
    [J]. Experimental Hematology & Oncology, 6
  • [7] Compassionate Use of Ropeginterferon-Alfa-2b/P1101 for Treatment of High Risk Polycythemia Vera and Essential Thrombocythemia Patients Previously Controlled on Pegylated Interferon-Alfa-2a/Pegasys®
    Gilreath, Jeffrey A.
    Tashi, Tsewang
    Kim, Soo Jin
    Hickman, Kimberly
    Prchal, Josef T.
    [J]. BLOOD, 2018, 132
  • [8] Efficacy of PEG-IFN-alfa 2a(Pegasys) vs Pegasys and RBV for HIV/HCV coinfected patients that are nonresponders to previous IFN therapy.
    Rodriguez-Torres, M
    Rodriguez-Orengo, J
    [J]. HEPATOLOGY, 2003, 38 (04) : 325A - 325A
  • [9] Histomorphological Responses after Therapy with Pegylated Interferon Alpha-2a in Patients with Essential Thrombocythemia (ET) and Polycythemia Vera (PV)
    Masarova, Lucia
    Yin, C. Cameron
    Cortes, Jorge E.
    Konopleva, Marina
    Borthakur, Gautam
    Newberry, Kate J.
    Kantarjian, Hagop M.
    Bueso-Ramos, Carlos E.
    Verstovsek, Srdan
    [J]. BLOOD, 2016, 128 (22)
  • [10] Complete Hematological, Molecular and Histological Remissions without Cytoreductive Treatment Lasting After Pegylated-Interferon α-2a (peg-IFNα-2a) Therapy in Polycythemia Vera (PV): Long Term Results of a Phase 2 Trial
    Turlure, Pascal
    Cambier, Nathalie
    Roussel, Murielle
    Bellucci, Sylvia
    Zini, Jean-Marc
    Rain, Jean-Didier
    Rousselot, Philippe
    Vainchenker, William
    Abdelkader, Lina
    Ghomari, Kamel
    Dutel, Jean-Luc
    Chait, Yasmine
    Chevret, Sylvie
    Chomienne, Christine
    Cassinat, Bruno
    Kiladjian, Jean-Jacques
    [J]. BLOOD, 2011, 118 (21) : 129 - 130
1234